Rhenman & Partners Asset Management Ab Axsome Therapeutics, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $854 Million
- Q3 2025
A detailed history of Rhenman & Partners Asset Management Ab transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 172,800 shares of AXSM stock, worth $24.1 Million. This represents 2.46% of its overall portfolio holdings.
Number of Shares
172,800
Previous 90,800
90.31%
Holding current value
$24.1 Million
Previous $9.48 Million
121.42%
% of portfolio
2.46%
Previous 1.24%
Shares
9 transactions
Others Institutions Holding AXSM
# of Institutions
423Shares Held
37.2MCall Options Held
752KPut Options Held
541K-
Vanguard Group Inc Valley Forge, PA4.16MShares$582 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$461 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA1.33MShares$186 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY1.12MShares$156 Million1.82% of portfolio
-
Macquarie Group LTD Australia, C31.08MShares$151 Million0.16% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $5.99B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...